MXPA97009396A - Derivatives of phenylpiperazine for the treatment of disorders of the dopam system - Google Patents

Abstract

The present invention relates to: Compounds of the general Formula (I) wherein R 1 and R 3 are each independently hydrogen atom, aryl radical, carbamoyl, lower alkylcarbonyl, lower alkyl, halogen, lower alkylcarbonylamino, lower alkenyl -carbonylamino, amino, arylamino, aryloxy, nitro, arylacetyl, lower alkanoyl-lower alkyl, alkylsulfonylamino, ureido or furan-2-yl-carbonylamino and R2 is a hydrogen atom, a lower alkyl radical, trifluoromethyl, halogen, lower alkoxy, alkyl lower carbonyl or lower alkylcarbonylamino, or R1 and R2 together can be a radical -OCH2O-, -O (CH2) 2O- or- (CH2) 3- R4 is a hydrogen atom, a halogen radical, hydroxy, lower alkyl , lower alkoxy or nitro, R5 is a hydrogen atom, a halogen radical or lower alkoxy, R6 is a hydrogen atom, a lower alkyl, halogen, hydroxy, amino, lower alkoxy, trifluoromethyl, nitro or lower alkyl-carbonyl radical amino, and R7 is a hydrogen atom or a lower alkyl-carbonyl radical, as well as pharmaceutically acceptable salts of the compounds of Formula (I), for the treatment or prevention of diseases that are caused by disorders of the dopamine system and, respectively, the production of the corresponding medicament

Description

DERIVATIVES OF PHENOXIPIPERAZINE FOR THE TREATMENT OF DISORDERS OF THE DOPAMINE SYSTEM BACKGROUND OF THE INVENTION The present invention relates to aromatic ethers, especially phenoxypiperazine derivatives of the General Formula wherein: R 1 and R 3 are each independently a hydrogen atom, an aryl radical, carbamoyl, lower alkylcarbonyl, lower alkyl, halogen, lower alkylcarbonylamino, lower alkenylcarbonylamino, amino, arylamino, aryloxy, nitro, arylacetyl , lower alkanoyl-lower alkyl, alkylsulfonylamino, ureido or furan-2-yl-carbonylamino and 2 R is a hydrogen atom, a lower alkyl radical, trifluoromethyl, halogen, lower alkoxy, lower alkyl-carbonyl or lower alkyl-carbonylamino, or REF: 26211 R1 and R2 together can be a radical -OCH2O-, -0 (CH2) 0 or - (CH2) 3-4 R is a hydrogen atom, a halogen radical, hydroxy, lower alkyl, lower alkoxy or nitro, R is a hydrogen atom, a halogen radical or lower alkoxy, R is a hydrogen atom, a lower alkyl, halogen, hydroxy, amino, lower alkoxy, trifluoromethyl, nitro or lower alkyl-carbonylamino radical, and? R is a hydrogen atom or a lower alkyl-carbonyl radical, as well as pharmaceutically acceptable salts of the compounds of Formula I. These compounds and salts are known. The manufacture of the aforementioned compounds, as well as their use as antihypertensive agents, are described in DE-OS patent 1964423. As used herein, the term "lower alkyl" means a straight or branched chain alkyl group of 1 to 6 carbon atoms, for example a methyl, ethyl or isopropyl, butyl, pentyl group and the like. The term "lower alkoxy" denotes - alkyl ether groups in which the lower alkyl radical is as previously described, for example methoxy, ethoxy, isopropoxy and the like. The term "halogen" means a chlorine, bromine, fluorine and iodine atom. Of the halogens, fluorine and chlorine are preferred. The amino group, if desired, may be substituted with a lower alkyl group of 1 to 6 carbon atoms such as, for example, methyl-, ethyl-, propyl-, butyl- or pentyl-amino and the like. The term "lower alkenyl" denotes a straight or branched olefinic chain of unsaturated hydrocarbon groups having from 2 to 6 carbon atoms. The term "aryl" denotes a phenyl or phenyl radical bearing a lower alkyl of 1 4 carbon atoms. Of these, p-tolyl is preferred. Surprisingly, it was found that these compounds can be used in the control or prevention of diseases that are caused by disorders of the dopamine system. These disorders include psychotic diseases such as, for example, schizophrenia. The objective of the present invention, accordingly, is the use of compounds of the formula I for the treatment or prevention of psychotic diseases that are caused by disorders of the dopamine system and the use of these compounds as active ingredients in the production of medications for that purpose, as well as medications that contain these compounds. The new pharmacological properties of these compounds have a high selective affinity for a neuroreceptor, especially the dopamine D4 receptor. Thus, it can be expected that when these compounds are used, there will be significantly fewer side effects than in the case of the known classical neuroleptic agents, for example haloperidol, which, as is known, binds to the D2 receptors or D3. It has been found that in the case of schizophrenia, the density of receptors D2 and D3 is increased by approximately 10%, while in the case of the D4 receptor, it can be increased by approximately 600% (TIPS, July 1994, vol. 15, pp. 264-270). Description of the test The compounds were characterized by their binding behavior to the D4 receptor. The compounds that were also expected to have good selectivity, the D2 receptor was compared with respect to its activity. In the test, CHO cells (Chinese hamster ovary cells) were used. Crude membranes were isolated by ultracentrifugation of D4-CHO and D2-CHO cells and stored at -80 ° C. After thawing and homogenising in a buffer solution (50 mM TRIS, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl 2, 4 mM MgCl 2, pH 7.4), they were incubated at room temperature for 90 min with [H] 200 pM spiperone and with a growing concentration (from 1 x 10 -11 M to 1 x 10-4 M) of the test compound. A non-specific binding was established by incubating in the presence of (+) -butaclamol 1 x 10"M. The unbound radioligand was removed by filtration through a GF / C glass filter and the bound radioactivity was determined by scintillation in a kit. Packard TopCount The following table shows the binding behavior of some selected compounds, on the D4 receptor, the Ki value is a binding constant that shows the activity of the compounds by the D4 receptor, it was determined using H-spiperone. The calculation of the value was made with the ligand.

Table 1 Particularly active compounds are presented in Table 1. These are the following compounds: 1-phenoxy-3- (4-phenylpiperazin-1-yl) -propan-2-ol; 2 1- (2-aminophenoxy) -3- (4-phenylpiperazin-1-yl) -propan-2-ol; 3 1- [2- [2-hydroxy-3- (4-phenylpiperazin-1-yl) -propoxy] -phenyl] -ethanone; 4 2- [2-hydroxy-3- (4-phenylpiperazin-1-yl) -propoxy] -benzamide; 5 1- [4- (4-chlorophenyl) -piperazin-1-yl] -3- (3-trifluoromethylphenoxy) -propan-2-ol; 6 N- [2- [2-hydroxy-3- (4-o-tolyl-piperazin-1-yl) -propoxy] -phenyl] -acetamide; 7 N- [2- [2-hydroxy-3- [4- (2-trifluoromethyl-phenyl) -piperazin-1-yl] -propoxy] -phenyl] -acetamide; 8 N- [2- [2-hydroxy-3- [4- (2-hydroxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -acetamide; 9 [+] -1- (2-aminophenoxy) -3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propan-2-ol; 10 N- [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -acetamide; 11 [+] - N - [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -acetamide; 12 [-] - N - [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -acetamide; 13 N- [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -propionamide; 14 [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -amide hexanoic acid; 15 N- [2- [2-hydroxy-3- [4- (2-methoxyphenyl-piperazin-1-yl] -propoxy] -phenyl] -2,2-dimethylpropionamide; 16 [+] - (E) - acid but-2-enol of [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -amide; 17 furan-2-carboxylic acid from [2 - [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -phenyl] -amide; 18 [2- [2-hydroxy-3- [4- (2-methoxyphenyl ) -piperazin-1-yl] -propoxy] -phenyl] -urea; 19 N- [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -5 -methylphenyl] -acetamide; 20 N- [2- [2-hydroxy-3- [4- (2-methoxyphenyl) -piperazin-1-yl] -propoxy] -4-methylphenyl] -acetamide; 21 N- [2 - [3- [4- (2-ethoxyphenyl) -piperazin-1-yl] -2-hydroxypropoxy] -phenyl] -propionamide; 1- (2-aminophenoxy) -3- [4- (2-nitrophenyl) - piperazin-1-yl] -propan-2-ol; 30 2- (2-acetylaminophenoxy) -1- [4- (2-methoxyphenyl) -piperazin-1-yl-methyl] -acetic acid ethyl ester and 31 [+] -2- (2-Acetylaminophenoxy) -l- [4- (2-methoxyphenyl) -piperazin-1-yl-methyl] -acetic acid ethyl ester Table 2 presented This shows clearly the selectivity of some compounds with respect to the D2 receptor, expressed by the ratio of the Ki values in the D4 receptor and in the D2 receptor.

Table 2 The compounds of Formula I and the pharmaceutically acceptable salts thereof can be used as medicaments, for example in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, for example in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, for example in the form of suppositories, or parenterally, for example in the form of injectable solutions. The compounds of Formula I and the pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, organic or inorganic carriers, for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example as carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like.; however, depending on the nature of the active ingredient, no vehicles are needed in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like can be used for aqueous injectable solutions of water-soluble salts of the compounds of Formula I, but as a general rule they are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

In addition, the pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, pH regulators, coating agents or antioxidants. They may also contain other substances of therapeutic value. As mentioned above, medicaments containing a compound of Formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert excipient, are also an object of the present invention, as is the process for the production of such medicaments, which comprises preparing one or more compounds of Formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other substances of therapeutic value, in a galenic administration form together with one or more therapeutically inert carriers. The dose can vary within a wide range and, of course, will be adjusted to the individual needs of each particular case. In general, a dose of about 1 to 1,000 mg per day would be appropriate. Finally, as mentioned above, the use of the compounds of Formula I and pharmaceutically suitable salts thereof for the production of drugs, especially for the control or prevention of diseases that are caused by disorders of the dopamine system, is also a object of the present invention. EXAMPLE A Tablets having the following composition were produced in the usual manner: mg / tablet Active ingredient 100 Lactose powder 95 White corn starch 35 Polyvinylpyrrolidone 8 Sodium carboxymethylstarch 10 Magnesium stearate 2 Tablet weight 250 EXAMPLE B Tablets were prepared the following composition in the usual manner: mg / tablet Active ingredient 200 Lactose powder 100 White corn starch 64 Polyvinylpyrrolidone 12 Sodium carboxymethylstarch 20 Magnesium stearate 4 Tablet weight 400 EXAMPLE C Capsules of the following composition were prepared: mg / capsule Active ingredient 50 Crystalline lactose 60 Microcrystalline cellulose 34 Talcum 5 Magnesium stearate 1 Weight of the capsule filled 150 The active ingredient with a particle size • suitable, the crystalline lactose and the microcrystalline cellulose are mixed homogeneously, sieved and then mixed with talc and magnesium stearate.

With the final mixture fill hard gelatin capsules of a suitable size. It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is the conventional one for the manufacture of the objects to which it relates. Having described the invention as an antecedent, what is contained in the following is claimed as property.

Claims (7)

1. CLAIMS 1. The use of compounds of the general Formula I characterized in that R 1 and R 3 are each independently a hydrogen atom, an aryl radical, carbamoyl, lower alkylcarbonyl, lower alkyl, halogen, lower alkylcarbonylamino, lower alkenylcarbonylamino, amino, arylamino, aryloxy, nitro, arylacetyl, lower alkanoyl-lower alkyl, alkylsulfonylamino, ureido or furan-2-yl-carbonylamino and R is a hydrogen atom, a lower alkyl radical, trifluoromethyl, halogen, lower alkoxy, lower alkylcarbonyl or lower alkylcarbonylamino, or R 1 and R2 together can be a radical -OCH20-, -0 (CH2) 20- or - (CH2) 3-4 R is a hydrogen atom, a halogen radical, hydroxy, lower alkyl, lower alkoxy or nitro, R is a hydrogen atom, a halogen radical or lower alkoxy , R is a hydrogen atom, a lower alkyl, halogen, hydroxy, amino, lower alkoxy, trifluoromethyl, nitro or lower alkyl-carbonylamino radical, and R is a hydrogen atom or a lower alkyl-carbonyl radical, as well as the salts pharmaceutically acceptable compounds of the Formula I, for the treatment or prevention of diseases that are caused by disorders of the dopamine system and, respectively, for the production of the corresponding drugs.
2. 2. Use in accordance with the claim 1 of the compounds of the general formula I as defined in claim 1, characterized in that R 2 is a hydrogen atom or a methyl radical, R is a hydrogen atom, a trifluoromethyl or methyl radical, R is a hydrogen atom , a hydroxy radical or halogen, R 5 is a hydrogen atom and R 3, R 6 and R 7 have the meanings set forth in claim 1.
3. 3. The use according to any of claims 1 or 2 in psychotic diseases.
4. 4. The use according to claim 3 in schizophrenia.
5. 5. The use according to any of claims 1 to 4, characterized by a dose of 1 to 1,000 mg per day.
6. 6. A medicament for use in diseases that are caused by disorders of the dopamine system, characterized in that it contains a compound according to any of claims 1 or 2 and a therapeutically inert carrier. A method for the treatment or prevention of diseases that are caused by disorders of the dopamine system, characterized in that it comprises the administration of an effective dose of a compound according to any of claims 1 or 2. SUMMARY OF THE INVENTION The present invention relates to compounds of the general Formula (I) wherein R 1 and R 3 are each independently a hydrogen atom, an aryl radical, carbamoyl, lower alkylcarbonyl, lower alkyl, halogen, lower alkyl -carbonylamino, lower alkenyl-carbonylamino, amino, arylamino, aryloxy, nitro, arylacetyl, lower alkanoyl-lower alkyl, alkylsulfonylamino, ureido or furan-2-yl-carbonylamino and R is a hydrogen atom, a lower alkyl radical, trifluoromethyl, halogen, lower alkoxy, lower alkylcarbonyl or lower alkylcarbonylamino, or R 1 and R 2 together can be a radical -0CH20-, -0 (CH2) 20- or - (CH2) 3-, R4 is a hydrogen atom, a halogen radical, hydroxy, lower alkyl, lower alkoxy or nitro, R is an hydrogen, a halogen radical or lower alkoxy, R is a hydrogen atom, a lower alkyl, halogen, hydroxy, amino, lower alkoxy, trifluoromethyl, nitro or lower alkylcarbonylamino radical, and R is a hydrogen atom or an alkyl radical lower carbonyl, as well as pharmaceutically acceptable salts of the compounds of the Formula (I), for the treatment or prevention of diseases that are caused by disorders of the dopamine system and, respectively, for the production of the corresponding medicaments.